When we start the new Olympic thread- the idea will be just the very best of the best... We will have a barbell approach. EBAY is one side of the barbell. Kratos Defense should probably go in. I had these guys on and off over the years and it's a frustrating stk for all they have accomplished it should be up more. Still these guys are the drone guys and at one point I thought they got bought out was it L3? but they pivoted and went with another stoned investing fave AJRD Aeorjet Rocketdyne! So Kratos is a good and company and probably a buyout candidate. this is cool--> KTOS developing hypersonic flight experiment test vehicle 08:05 KTOS Is this in response to the mysterious UFO's of late...
SPRO never pulled in/ What happened Shares of small-cap biopharma company Spero Therapeutics (NASDAQ:SPRO) are up 15.3% as of midday Thursday after announcing a new product partnership with Pfizer (NYSEFE), in addition to a major equity investment by the same pharmaceutical icon. Namely, Pfizer is now a licensee of Spero's drug-resistant infection treatment SPR206, as well as an owner of about $40 million worth of Spero Therapeutics. That's nearly a 10th of the small company. So what The move is a somewhat risky one on Pfizer's part. Spero is not yet generating any product revenue, and SPR206 is only in the midst of phase 1 trials as a treatment for multidrug-resistant (or MDR), Gram-negative infections. The company's most-developed project is a treatment for urinary tract infections called Tebipenem HBr. It's only recently completed phase 3 trials, though, and has yet to be submitted to regulators for final approval. The need for new ways of fighting bacterial infections is tremendous, though, as older drugs are less and less effective. Bacteria evolve and adapt, too, as a means of working around previously effective therapies. The World Health Organization deems antibiotic resistance as one of today's most significant threats to human health. Now what While $40 million is a significant sum to Spero Therapeutics, given its $478 million market cap, it's not a particularly large sum to Pfizer. If for some reason SPR206 isn't approved, the pharmaceutical giant is no worse off. Pfizer's interest in a controlling stake in a small biopharma name like Spero is telling all the same, though, as is its specific licensing interest in such an early-stage drug. Thursday's surge might well be met with some profit taking, but investors should see this development in a bigger-picture context: The tie-up serves as a vote of confidence in Spero and its pipeline.
A) Granite Construction Incorporated (GVA) NYSE - Nasdaq Real Time Price. Currency in USD $42.28+0.75 (+1.81%) As of 1:46PM EDT.
B) WideOpenWest, Inc. (WOW) NYSE - Nasdaq Real Time Price. Currency in USD about to break over 52 week high) $21.41+0.70 (+3.36%) As of 1:50PM EDT.
C) Kratos Defense & Security Solutions, Inc. (KTOS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD $28.35-0.15 (-0.51%)
Apple opens its App Store to marijuana delivery companies Jul. 01, 2021 iQoncept/iStock via Getty Images In a policy update last month, Apple (AAPL-0.6%) has allowed the marijuana delivery services to operate on its App Store. The pot delivery services will no longer be barred from being hosted on the App Store as long as the app is geo-restricted to areas where cannabis is legal,MarijuanaMomentreported.
Man this was some sort of flash up... ? If I had been home I would of had a good sell. I only learned after the close. Strange. 1stdibs.com(NASDAQ:DIBS)ended the day with a monster gain of 40.8%. Shares traded as high as $35.30 to mark a post-IPO high. The online antiques platform raised $115M after pricing its IPO at $20 share. The company expects to use the proceeds for working capital, sales and marketing, technology, general and administrative, capital expenditures and potential future M&A activity. Meanwhile, Newegg Commerce(NASDAQ:NEGG) jumped 78.3% and reached a high of $19.22 in a similar momentum-driven move.
Wouldn't it be ironic if the market sold off right as Robin Hood files. Hot investing app Robinhood Markets Inc. (HOOD) filed Thursday for an eagerly anticipated IPO at a $100M placeholder value. Robinhood said in an S-1 filing with the U.S. Securities and Exchange Commission that it plans to list on the Nasdaq under the ticker symbol “HOOD.” Not loving the symbol. Why not just call it MADOFF
1.-WideOpenWest (WOW) upgraded to Strong Buy from Market Perform at Raymond James with analyst Frank Louthan saying the "transformational deal" to divest five legacy markets renews the company's growth outlook. 2- WideOpenWest price target raised to $26 from $21 at KeyBanc 3- WideOpenWest price target raised to $30 from $28 at B. Riley » Benchmark constructive on WideOpenWest's deleveraging transaction 10:42 WOW Benchmark analyst Matthew Harrigan is constructive on WideOpenWest's announcement that it is selling two service areas to Atlantic Broadband and Astound Broadcasting at an 11-times composite Adjusted EBITDA multiple. Totalproceeds for the sale of nearly 38% of subscriber relations and 36% of Adjusted EBITDA on a pro forma basis are near $1.8B, Harrigan adds. The analyst acknowledges that the sale, however, does materially reduce WideOpenWest's operating scale. Harrigan does not anticipate any regulatory issues that would delay a second half 2021 closing. He has a Buy rating and a price target of $25 on the shares. WOW-$21.39
UMG and SNAP huh? That's why I know their revenue is gonna shatter their previous records... maybe not so much on the UMG deal, but they have been spending money on more and more tech. If I recall they bought some company a few months back. Augmented reality stuff. But that UMG deal... that's great news for SNAP. And we all know who's calling some of the shots over there now... Sir Bill Ackman. I've said it all along, as Wall Streeter's go, Ackman's the best there is. I know RBLX is in our G4G portfolio, but I kinda laugh.... it may be a high growth darling, but its user base and ability to generate revenue doesn't hold a candle to Snapchat. They say that 80% of Americans under 30 use SnapChat at least once a day. With AI generating targeted ads.... omg.... as the roaring 20's have kicked in and the lock-downs have ended, you know damn well advertisers have been beating SNAP's doors down. In the race to $125, SNAP is gonna leave RBLX in the dust. If Wall Street wants to pay up for growth.... it's the proverbial "best of breed".